Rapamycin, anti-aging, and avoiding the fate of Tithonus

Journal of Clinical Investigation

Volumn 123, Issue 8, 2013, Pages 3204-3206

  Richardson, Arlan ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

AGING; ALZHEIMER DISEASE; BONE MARROW SUPPRESSION; CAUSE OF DEATH; DIET RESTRICTION; DRUG ERUPTION; GRIP STRENGTH; HEALTH STATUS; HUMAN; HUNTINGTON CHOREA; HYPERGLYCEMIA; HYPERLIPIDEMIA; INCIDENCE; INTERSTITIAL PNEUMONIA; LIFESPAN; LONGEVITY; MORTALITY; MUSCULAR DYSTROPHY; NEPHROTOXICITY; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PUBLIC FIGURE; QUALITY OF LIFE; REVIEW; ROTAROD TEST; STOMATITIS; TIME OF DEATH;

AGING; ANIMALS; LONGEVITY; MALE; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84881237963     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70800     Document Type: Review

References (23)

1. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
2. Neff F, et al. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013;123(8):3272-3291.
3. Halloran J, et al. Chronic inhibition of mTOR by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience. 2012;223:102-113.
4. Majumder S, et al. Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and NMDA signaling. Aging Cell. 2012;11(2):326-335.
5. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mTOR, amyloid-beta, and tau: Effects on cognitive impairments. J Biol Chem. 2010;285(17):13107-13120.
6. Spilman S, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-β levels in a mouse model of Alzheimer's disease. PLoS One. 2010;5(4):e9979.
7. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before but not after plaques and tangles formation ameliorates cognitive deficits in a mouse model of Alzheimer's disease. PLoS One. 2011;6(9):e25416.
8. Ramos FJ, et al. Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med. 2012;4(144):144ra103.
9. Zhang Y, et al. Rapamycin extends life and health in C57BL/6 mice [published online ahead of print May 16, 2013]. J Gerontol A Biol Sci Med Sci. doi:10.1093/gerona/glt056.
10. Ravikumar B, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36(6):585-595.
11. Wilkinson JE, et al. Rapamycin slows aging in mice. Aging Cell. 2012;11(4):675-682.
12. Ikeno Y, Lew CM, Cortez LA, Webb CR, Lee S, Hubbard GB. Do long-lived mutant and calorierestricted mice share common anti-aging mechanisms? - a pathological point of view. Age (Dordr). 2006;28(2):163-171.
13. Miller RA, et al. Rapamycin, but not resveratrol or simvastatin, extends lifespan of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011;66(2):191-20.
14. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A. 2008;105(36):13544-13549.
15. Comas M, et al. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY). 2012;4(10):715-722.
16. Anisimov VN, et al. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010;175(5):2092-2097.
17. Livi CB, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. Aging (Albany NY). 2013;5(2):100-110.
18. Richardson A, McCarter R. Mechanism of food restriction: change of rate or change of set point? In: Ingram DK, Baker GT, Shock NW, eds. The Potential for Nutritional Modulation of Aging Processes. Trumbull, Connecticut, USA: Food and Nutrition Press, Inc.; 1991:177-192.
19. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis. 2008;198(1):39-48.
20. Cohen EEW. mTOR: The mammalian target of replication. J Clin Oncol. 2008;26(3):348-349.
21. Scott A, Karnad S, Karnad A, Brenner AJ. Common toxicities of mammalian target of rapamycin inhibitors. Target Oncol. 2011;6(2):125-129.
22. Hinojosa CA, et al. Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence. Exp Gerontol. 2012;47(12):958-965.
23. Mita M, Mita A. Are we ready to move away from nature? The rapamycin story. Target Oncol. 2011;6(2):63-64.